U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07133685) titled 'Evaluation of Serum IL-7 as a Biomarker in Breast Cancer' on Aug. 14.
Brief Summary: Breast cancer is one of the most commonly diagnosed cancers and leading cause of cancer-related mortality in women worldwide, posing a serious threat to their health (1).
It is a heterogeneous disease, characterized by varying molecular subtypes such as hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2-positive), and triple-negative breast cancer (TNBC) (2).
Breast cancer develops as a result of several internal and external factors (3-5). Poor lifestyle choices, environmental factors, and social-psychological factors...